Biopharmaceutic and pharmacodynamic modeling of the in vitro antiproliferative effect of new controlled delivery systems of cisplatin

European Journal of Pharmaceutical Sciences

Volumn 37, Issue 3-4, 2009, Pages 341-350

  Moreno, Daniel ^a   Zalba, Sara ^a   Colom, Helena ^b   Trocóniz, Iñaki F ^a   Tros de Ilarduya, Conchita ^a   Garrido, María J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Biopharmaceutic pharmacodynamic modeling; Cisplatin antiproliferative effect; PLGA cisplatin nanoparticles; PLGA cisplatin microparticles

Indexed keywords

CASPASE 3; CISPLATIN; POLYGLACTIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL DEATH; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROL SYSTEM; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CYTOTOXICITY; DEGRADATION; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EXPOSURE; DRUG RELEASE; ENCAPSULATION; ENZYME ACTIVATION; IN VITRO STUDY; IN VIVO CULTURE; LOADING DRUG DOSE; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BIOPHARMACEUTICS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CISPLATIN; DELAYED-ACTION PREPARATIONS; DIFFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; LACTIC ACID; PARTICLE SIZE; POLYGLYCOLIC ACID;

EID: 67349122317     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.03.005     Document Type: Article

References (40)

1. Anderso J.M., and Shive M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28 (1997) 5-24
2. Akaike H. An information criterion (AIC). Math. Scientist 14 (1976) 5-9
3. Augey V., Cociglio M., Galtier M., Yearoo R., Pinsani V., and Bressolle F. High-performance liquid chromatographic determination of cis-dichlorodiammineplatinum (II) in plasma ultrafiltrate. J. Pharm. Biomed. Anal. 13 (1995) 1173-1178
4. Avgustakis K., Beletsi A., Panagi P., Karydas A.G., and Ithakissios D.S. PLGA-mPEG nanoparticles of cisplatin: "in-vitro" nanoparticle degradation, "in-vitro" drug release and "in-vivo" drug resistance in blood properties. J. Control. Release 79 (2002) 123-135
5. Baker R.W., and Lonsdale H.S. Controlled release: mechanisms and rates. In: Taquary A.C., and Lacey R.E. (Eds). Controlled Release Biologically Active Agents (1974), Plenum Press, New York 15-71
6. Beal S., and Sheiner L. NONMEM User's Guides (1992), University of California, San Francisco
7. Belic A., Grabnar I., Karba R., and Mrhar A. Pathways of paracetamol absorption from layered excipient suppositories: artificial intelligence approach. Eur. J. Drug Metab. Pharmacokinet. 28 (2003) 31-40
8. Berndtsson M., Hägg M., Panaretakis T., Havelka A.M., Shoshan M.C., and Linder S. Acute apoptosis by cisplatin requires induction of reactive species but is not associated with damage to nuclear DNA. Int. J. Cancer 120 (2007) 175-180
9. Birdsey G.M., Dryden N.H., Amsellem V., Gebhardt F., Sahnan K., Haskard D.O., Dejana E., Mason J.C., and Randi A.M. Transcription factor Erg regulates angiogenesis and endothelial apotosis through VE-cadherin. Blood 111 (2008) 3498-3506
10. Costa P., and Sousa Lobo J.M. Modeling and comparison of dissolution profiles. Rev. Eur. J. Pharm. Sci. 13 (2001) 123-133
11. Cummings B.S., and Schnellmann R.G. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J. Pharmacol. Exp. Ther. 302 (2002) 8-17
12. Díez S., and Tros de Ilarduya C. Versatility of biodegradable poly(d, l-lactic-co-glycolic acid) microspheres for plasmid DNA delivery. Eur. J. Pharm. Biopharm. 63 (2006) 188-197
13. Duvvuri S., Gaurav K., and Mitra A.K. Effects of polymer blending on the release of Ganciclovir from PLGA microspheres. Pharm. Res. 23 (2006) 215-223
14. González V.M., Fuertes M.A., Alonso C., and Perez J.M. Is cisplatin-induced cell death always produced by apoptosis?. Mol. Pharmacol. 59 (2001) 657-663
15. Hamelers I.H., van Loenen E., Staffhorst R.W., de Kruijiff B., and de Kroon A.I. Carboplatin nanocapsules: a highly cytotoxic phospholipids-based formulation carboplatin. Mol. Cancer Ther. 5 (2006) 2007-2012
16. Harashima H., Tsuchihaschi M., Iida S., Doi H., and Kiwada H. Pharmacokinetic/pharmacodynamic modeling of antitumor agents encapsulated into liposomes. Adv. Drug Deliv. Rev. 40 (1999) 39-61
17. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of the rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci. 52 (1963) 1145-1149
18. Hopfenberg H.B. In: Paul D.R., and Harris F.W. (Eds). Controlled release polymeric formulations. ACS Symposium Series 33 (1976), American Chemical Society, Washington, DC 26-31
19. Huo D., Deng S., Li L., and Ji J. Studies on the poly(lactic-co-glycolic) acid microspheres of cisplatin for lung-targeting. Int. J. Pharm. 289 (2005) 63-67
20. Iinuma H., Maruyama K., Okinaga K., Sasazi K., Sekine T., Ishida O., Ogiwara N., Johkura K., and Yonemura Y. Intracellular targeting therapy of cisplatin -encapsulates transferring-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int. J. Cancer 99 (2002) 130-137
21. Kartalou M., and Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat. Res. 478 (2001) 23-43
22. Kim C.J. Controlled Release Dosage Form Design, Technomic Lancaster (2000), CRC Press pp. 13-82
23. Kim J.H., Kim Y.S., Park K., Lee S., Nam H.Y., Min K.H., Jo H.G., Park J.H., Choi K., Jeong S.Y., Park R.W., Kim I.S., Kim K., and Kwon I.C. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J. Control. Release 127 (2008) 41-49
24. Kishimoto S., Kawazoe Y., Ikeno M., Fukushima S., and Takeuchi Y. Continuous exposure to low-dose cisplatin and apoptosis. Biol. Pharm. Bull. 28 (2005) 1954-1957
25. Klose D., Siepmann F., Elkharraz K., Krenzlin S., and Siepmann J. How porosity and size affect the drug release mechanisms from PLGA-based microparticles. Int. J. Pharm. 314 (2006) 198-206
26. Korsmeyer R.W., Gurny R., Doelker E., Buri P., and Peppas N.A. Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm. 15 (1983) 25-35
27. Koziara J.M., Whisman T.R., Tseng M.T., and Mumper J.R. In-vivo" efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J. Control. Release 112 (2006) 312-319
28. Löwik C.W.G.M., Alblas M.J., van de Ruit M., Papapoulos S.E., and van der Pluijm G. Quantification of adherent and nonadherent cells cultured in 96-well plates using the supravital stain neutral red. Anal. Biochem. 213 (1993) 426-433
29. Moreno D., de Ilarduya C.T., Bandrés E., Buñuales M., Azcona M., García-Foncillas J., and Garrido M.J. Characterization of the cisplatin cytotoxicity delivery from PLGA-systems. Eur. J. Pharm. Biopharm. 68 (2008) 503-512
30. Moreno D., Trocóniz I.F., Enguita M., Bandrés E., García-Foncillas J., and Garrido M.J. Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumor agents. J. Pharm. Pharmacol. 60 (2008) 77-82
31. Mueller S., Schittenhelm M., Honecker F., Malenke E., Lauber K., Wesselborg S., Hartmann J.T., Bokemeyer C., and Mayer F. Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. Int. J. Oncol. 29 (2006) 471-479
32. Ormerod M.G., Orr R.M., and Peacock J.H. The role of apoptosis in cell killing by cisplatin: a flow cytometric study. Br. J. Cancer 69 (1994) 93-100
33. Peppas N.A. Analysis of Fickian and non-Fickian drug release from polymers. Pharm. Acta Helv. 60 (1985) 110-111
34. Peppas N.A., and Sahlin J.J. A simple equation for description of solute release. III. Coupling of diffusion and relaxation. Int. J. Pharm. 57 (1989) 169-172
35. Rice J.R., Gerberich J.L., Nowotnik D.P., and Howell S.B. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin. Cancer Res. 12 (2006) 2248-2254
36. Ritger P.L., and Peppas N.A. A simple equation for description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J. Control. Release 5 (1987) 23-36
37. Verrijk R., Smolders I.J., Bosnie N., and Begg A.C. Reduction of systemic exposure and toxicity of cisplatin by encapsulation in poly-lactide-co-glycolide. Cancer Res. 52 (1992) 6653-6656
38. Wen-tao Q., Ying Z., Juan M., Xin G., Yu-bing X., Wei W., and Xiaojun M. Optimization of the cell seeding density and modelling of cell growth and metabolism using the modified Gompertz model for microencapsulated animal cell culture. Biotechnol. Bioeng. 93 (2006) 887-895
39. William-Faltaos S., Rouillard D., Lechat P., and Bastian G. Cell cycle arrest by oxaliplatin on cancer cells. Fundam. Clin. Pharmacol. 21 (2007) 165-172
40. Wu Y.J., Muldoon L.L., and Neuwelt E.A. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signalling pathway. J. Pharmacol. Exp. Ther. 312 (2004) 424-431